NCT06182839View on ClinicalTrials.gov

Canagliflozin in Advanced Renal Disease With MRI Endpoints

PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2029

Conditions
ESRD, CKD Stage 4, CKD Stage 5
Interventions
DRUG

Canagliflozin 300Mg Tab

Patients will get 1 pill of Canagliflozin 300 mg daily for one year.

DRUG

Placebo

Patients will get 1 pill of placebo daily for one year.

Trial Locations (1)

Unknown

RECRUITING

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER